Concomitant expression of the rare E1/A3 and B2/A3 types of BCR/ABL transcript in a chronic myeloid leukemia (CML) patient

Exceptional long-term responses from OCEAN and HORIZON trials: melflufen-dexamethasone as an expansion of treatment options for relapsed/refractory multiple myeloma in the era of new immunotherapies?

Journal of cancer research and clinical oncology·2025

Real-life use of ropeg-interferon α2b in polycythemia vera: patient selection and clinical outcomes.

Annals of hematology·2024

A venetoclax and azacitidine bridge-to-transplant strategy for NPM1-mutated acute myeloid leukaemia in molecular failure.

British journal of haematology·2023

: A copy number clustering tool designed to refit and recalibrate the baseline region of tumors' profiles.

Computational and structural biotechnology journal·2022

Clonal and subclonal TP53 molecular impairment is associated with prognosis and progression in multiple myeloma.

Blood cancer journal·2022

Concurrent chromothripsis events in a case of TP53 depleted acute myeloid leukemia with myelodysplasia-related changes.

Cancer genetics·2019

Clinical evaluation of AI-assisted quantitative marrow fibrosis assessment using Continuous Indexing of Fibrosis (CIF).

Leukemia·2026

Targeting CD38 with bispecific antibody XmAb 18968 in patients with relapsed/refractory acute myeloid leukemia and T-cell acute lymphoblastic leukemia.

Leukemia·2026

Circulating tumor cells identify a disseminated genomic high-risk phenotype within IMS-IMWG 2025 staging in newly diagnosed multiple myeloma.

Leukemia·2026

Functional characterization of snoRNA-derived RNA (sdRNA) expression in healthy hematopoiesis and acute myeloid leukemia.

Leukemia·2026

Csnk1a1 E98 mutations rewire signaling and metabolism in del(5q) myelodysplastic neoplasms.

Leukemia·2026

Patterns of clonal hematopoiesis in aplastic anemia under immunosuppressive therapy.

Leukemia·2026

Co-occurrence of GATA2 deficiency and probable constitutional mosaic STAG2 alteration in a young adult with myelodysplastic syndrome: a case report.

Frontiers in medicine·2026

Epstein-Barr virus reactivation and post-transplant lymphoproliferative disease risk deserve a place in the JAK inhibitor toxicity profile. Comment on: "Janus kinase inhibitors as an evolving treatment for lymphomas and immune-mediated complications".

Haematologica·2026

Venous Thromboembolism in Patients Treated with Everolimus: Insights from a Case Series and the French Pharmacovigilance Database.

Current vascular pharmacology·2026

Hepatocellular Carcinoma With JAK1 Mutations Harbors Distinct Histologic Features and Specific Mutational Hotspots in an Asian Cohort.

The American journal of surgical pathology·2026

TH/TRs-COL11A2 Axis Mediates Loss of a Differentiated Astrocyte State in Hypogyrified Brains.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2026

Functional contribution of Epstein-Barr virus BARF1 residues 35-39 to viable cell maintenance under serum deprivation and tumor formation.

Virus genes·2026

Related Experiment Videos

Concomitant expression of the rare E1/A3 and B2/A3 types of BCR/ABL transcript in a chronic myeloid leukemia (CML)

Related Concept Videos

Exceptional long-term responses from OCEAN and HORIZON trials: melflufen-dexamethasone as an expansion of treatment options for relapsed/refractory multiple myeloma in the era of new immunotherapies?

Real-life use of ropeg-interferon α2b in polycythemia vera: patient selection and clinical outcomes.

A venetoclax and azacitidine bridge-to-transplant strategy for NPM1-mutated acute myeloid leukaemia in molecular failure.

: A copy number clustering tool designed to refit and recalibrate the baseline region of tumors' profiles.

Clonal and subclonal TP53 molecular impairment is associated with prognosis and progression in multiple myeloma.

Concurrent chromothripsis events in a case of TP53 depleted acute myeloid leukemia with myelodysplasia-related changes.

Clinical evaluation of AI-assisted quantitative marrow fibrosis assessment using Continuous Indexing of Fibrosis (CIF).

Targeting CD38 with bispecific antibody XmAb 18968 in patients with relapsed/refractory acute myeloid leukemia and T-cell acute lymphoblastic leukemia.

Circulating tumor cells identify a disseminated genomic high-risk phenotype within IMS-IMWG 2025 staging in newly diagnosed multiple myeloma.

Functional characterization of snoRNA-derived RNA (sdRNA) expression in healthy hematopoiesis and acute myeloid leukemia.

Csnk1a1 E98 mutations rewire signaling and metabolism in del(5q) myelodysplastic neoplasms.

Patterns of clonal hematopoiesis in aplastic anemia under immunosuppressive therapy.

Co-occurrence of GATA2 deficiency and probable constitutional mosaic STAG2 alteration in a young adult with myelodysplastic syndrome: a case report.

Epstein-Barr virus reactivation and post-transplant lymphoproliferative disease risk deserve a place in the JAK inhibitor toxicity profile. Comment on: "Janus kinase inhibitors as an evolving treatment for lymphomas and immune-mediated complications".

Venous Thromboembolism in Patients Treated with Everolimus: Insights from a Case Series and the French Pharmacovigilance Database.

Hepatocellular Carcinoma With JAK1 Mutations Harbors Distinct Histologic Features and Specific Mutational Hotspots in an Asian Cohort.

TH/TRs-COL11A2 Axis Mediates Loss of a Differentiated Astrocyte State in Hypogyrified Brains.

Functional contribution of Epstein-Barr virus BARF1 residues 35-39 to viable cell maintenance under serum deprivation and tumor formation.

Related Experiment Videos

Concomitant expression of the rare E1/A3 and B2/A3 types of BCR/ABL transcript in a chronic myeloid leukemia (CML)...

Related Concept Videos

Related Articles

Concomitant expression of the rare E1/A3 and B2/A3 types of BCR/ABL transcript in a chronic myeloid leukemia (CML)